Core Insights - Microbot Medical Inc. has strengthened its U.S. commercial leadership team with the addition of a new Vice President of Marketing and a Director of Human Resources, preparing for the launch of its LIBERTY® Endovascular Robotic System [1][4][6] - Positive data from a pivotal study has increased confidence in the market reception of LIBERTY® [1] Leadership Additions - Allison Rosefort has been appointed as Vice President of Marketing, bringing over 15 years of experience in healthcare marketing and a proven track record of driving double-digit revenue growth [2][3] - Lisa Dobbins has joined as Director of Human Resources, with a background in building high-performing teams in the MedTech sector [4][5] Commercialization Strategy - The company aims to be ready for the immediate launch of LIBERTY® following FDA clearance, reflecting its commitment to establishing a robust commercial infrastructure [6] - The recent hiring of Paul Mullen as Vice President of Sales complements the new marketing and HR leadership, enhancing the company's commercialization readiness [1][6] Product Overview - LIBERTY® is an investigational device pending FDA 510(k) clearance and is not currently available for sale in the U.S. [6] - The device is designed to redefine endovascular robotics and improve patient care globally [7]

Core Insights - The LIBERTY® Endovascular Robotic System demonstrated successful robotic navigation in all cases, achieving a 100% success rate and meeting the primary endpoint of the ACCESS-PVI pivotal trial [1][8] - The system resulted in a 92% reduction in radiation exposure with no adverse device events reported, indicating its safety and efficacy [1][2][8] - The study was conducted at three leading medical centers in the U.S., showcasing the credibility of the results [1] Company Overview - Microbot Medical Inc. is a pre-commercial stage medical technology company focused on redefining endovascular robotics to enhance patient care globally [5] - The company has developed the first single-use, fully disposable endovascular robotic system, aiming to overcome traditional barriers in accessing advanced robotic systems [5] Clinical Study Highlights - The ACCESS-PVI study involved 20 cases, with a mean robotic navigation time to target of 3 minutes [8] - Participating physicians reported a 100% satisfaction rate with the performance of the LIBERTY® system [8] - The mean difference in radiation exposure between the operator and control was a reduction of 29.8 µS, confirming the system's effectiveness in minimizing radiation [8] Future Outlook - The company is preparing for the commercial launch of LIBERTY® and is confident in its market reception based on positive clinical data and feedback from investigators [4] - LIBERTY® is currently pending FDA 510(k) clearance and is not available for sale in the U.S. [4]